GALNT5 functions as a suppressor of ferroptosis and a predictor of poor prognosis in pancreatic adenocarcinoma.
GALNT5
ferroptosis
immune microenvironment
pan-cancer
pancreatic adenocarcinoma
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
06
2023
accepted:
22
08
2023
medline:
16
11
2023
pubmed:
16
11
2023
entrez:
16
11
2023
Statut:
epublish
Résumé
Mucin-type O-glycosylation, a posttranslational modification of membrane and secretory proteins, facilitates metastasis and immune escape in tumor cells. N-acetylgalactosaminyl-transferase 5 (GALNT5), the enzyme initiating mucin-type O-glycosylation, is known to advance the progression of various tumors. Yet, the comprehensive role of GALNT5 in pan-cancer scenarios remains to be elucidated. In this research, we conducted a database-centric pan-cancer expression analysis of GALNT5. We examined its aberrant expression, assessed its prognostic implications, and explored the correlations between GALNT5 expression and factors such as ferroptosis, immune cell infiltration levels, and immune checkpoint gene expression across multiple tumor types. To substantiate GALNT5's role, we analyzed cell proliferation, migration, invasion, and ferroptosis in PAAD cells after GALNT5 knockdown. Additionally, RNA-seq was employed to discern potential downstream pathways influenced by GALNT5. Our findings indicate that GALNT5 expression is heightened in the majority of tumors, correlating with the prognosis of multiple cancers. There's a notable association between GALNT5 levels and ferroptosis-related genes, immune cell infiltration, and immune checkpoint genes. In PAAD specifically, the role of GALNT5 was further probed. Knockdown of GALNT5 curtailed the proliferation, migration, and invasion capacities of PAAD cells, concurrently promoting ferroptosis. Moreover, in vivo studies demonstrated that GALNT5 inhibition stunted PAAD tumor growth. The RNA-seq analysis unveiled inflammation and immune-centric pathways, such as the TNF signaling pathway, as potential downstream conduits of GALNT5. In conclusion, our pan-cancer study underscores GALNT5 as a potential therapeutic target for enhancing PAAD prognosis, given its strong ties with ferroptosis and immune cell infiltration. Our experiments further define GALNT5 as a novel suppressor of ferroptosis.
Types de publication
Journal Article
Langues
eng
Pagination
4579-4596Informations de copyright
AJCR Copyright © 2023.
Déclaration de conflit d'intérêts
None.
Références
Cell Mol Biol Lett. 2022 Sep 4;27(1):71
pubmed: 36058918
Nat Rev Cancer. 2004 Jan;4(1):45-60
pubmed: 14681689
Oxid Med Cell Longev. 2022 Jul 21;2022:2405943
pubmed: 35910848
Front Immunol. 2023 Feb 28;14:1137107
pubmed: 36926345
Future Oncol. 2014 Dec;10(15):2449-57
pubmed: 25525853
Clin Cancer Res. 2017 Sep 1;23(17):5255-5266
pubmed: 28533224
Int J Biol Sci. 2022 Aug 29;18(14):5459-5474
pubmed: 36147463
Front Cell Dev Biol. 2021 Dec 13;9:797339
pubmed: 34966745
Front Mol Biosci. 2022 Jun 03;9:904098
pubmed: 35720126
Biomed Res Int. 2019 Nov 19;2019:2408348
pubmed: 31828095
Proc Natl Acad Sci U S A. 2022 Mar 15;119(11):e2118646119
pubmed: 35271393
J Hepatol. 2023 Feb;78(2):376-389
pubmed: 36455783
Am J Cancer Res. 2022 Sep 15;12(9):4140-4159
pubmed: 36225633
J Cancer Res Clin Oncol. 2023 Aug;149(9):6411-6434
pubmed: 36757621
Gut. 2023 Sep;72(9):1774-1782
pubmed: 36707233
Mar Drugs. 2021 Aug 14;19(8):
pubmed: 34436298
J Nanobiotechnology. 2022 Mar 27;20(1):161
pubmed: 35351131
J Cancer Res Clin Oncol. 2023 Jul;149(7):4047-4061
pubmed: 36038676
Glycobiology. 2012 Jun;22(6):736-56
pubmed: 22183981
iScience. 2020 Jul 24;23(7):101302
pubmed: 32629423
Front Immunol. 2022 Dec 09;13:1071636
pubmed: 36569869
Adv Mater. 2021 Aug;33(31):e2101155
pubmed: 34170581
FEBS Lett. 2019 Oct;593(19):2751-2761
pubmed: 31283009
Cancer Lett. 2023 May 1;561:216152
pubmed: 37023938
Free Radic Biol Med. 2019 Mar;133:162-168
pubmed: 29800655
Front Oncol. 2022 May 27;12:802548
pubmed: 35692787
Gastroenterol Jpn. 1987 Oct;22(5):640-6
pubmed: 2445616
Lancet. 2022 Aug 20;400(10352):563-591
pubmed: 35988567
BMC Cancer. 2018 Nov 22;18(1):1157
pubmed: 30466404
Cell Res. 2021 Feb;31(2):107-125
pubmed: 33268902
Cell Death Dis. 2022 Dec 21;13(12):1062
pubmed: 36539408
Front Oncol. 2023 May 02;13:1121258
pubmed: 37205199
Cell. 2022 Feb 3;185(3):576
pubmed: 35120665
J Cancer. 2022 Mar 6;13(5):1611-1622
pubmed: 35371305
J Clin Med. 2022 Dec 25;12(1):
pubmed: 36614956
Nature. 2019 May;569(7755):270-274
pubmed: 31043744
Trends Cell Biol. 2016 May;26(5):379-388
pubmed: 26832820
Glycobiology. 2020 Apr 20;30(5):312-324
pubmed: 31868214
Nat Rev Rheumatol. 2021 Apr;17(4):213-223
pubmed: 33686279
J Biol Chem. 2001 Jul 20;276(29):27371-5
pubmed: 11369781
Angew Chem Int Ed Engl. 2011 Feb 18;50(8):1770-91
pubmed: 21259410
Eur J Cancer. 1995 Jun;31A(6):899-902
pubmed: 7646918
Aging (Albany NY). 2023 Mar 25;15(6):2208-2220
pubmed: 37000153
Elife. 2014 Mar 11;3:e01828
pubmed: 24618899
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33188036
Int J Biol Sci. 2022 Oct 17;18(16):6068-6083
pubmed: 36439876
Nat Rev Cancer. 2015 Sep;15(9):540-55
pubmed: 26289314
Med Sci Monit. 2020 Dec 07;26:e927837
pubmed: 33284788
Pharmacol Res. 2022 Oct;184:106420
pubmed: 36049664
BMC Cancer. 2023 Feb 22;23(1):179
pubmed: 36814203
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Future Oncol. 2022 Jan;18(2):149-161
pubmed: 34643088
Glycobiology. 2022 Apr 21;32(5):366-379
pubmed: 34939098
Physiol Rev. 2019 Jan 1;99(1):115-160
pubmed: 30354964
Front Pharmacol. 2023 May 04;14:1153067
pubmed: 37214432
ACS Nano. 2023 Jun 27;17(12):11537-11556
pubmed: 37272777
Math Biosci Eng. 2019 Nov 6;17(1):910-927
pubmed: 31731384
Cells. 2022 Nov 18;11(22):
pubmed: 36429094
J Mol Cell Cardiol. 2022 Dec;173:75-91
pubmed: 36162497
J Toxicol Sci. 2023;48(5):299-310
pubmed: 37121744